Cost-effectiveness of pharmaceutical care on patients undergoing maintenance hemodialysis - a multicenter randomized controlled study.
Uday Venkat MatetiAnantha Naik NagappaRavindra Prabhu AtturShankar Prasad NagarajuDharshan RangaswamyPublished in: Postgraduate medicine (2018)
It depends upon the policymakers and regulators to take the decision, if they believe that the extra cost is worth the extra QALY.
Keyphrases
- double blind
- patients undergoing
- placebo controlled
- healthcare
- open label
- palliative care
- end stage renal disease
- phase iii
- chronic kidney disease
- quality improvement
- peritoneal dialysis
- clinical trial
- transcription factor
- decision making
- cross sectional
- pain management
- randomized controlled trial
- affordable care act
- chronic pain